Menu Search
Equities

IDEXX Laboratories Inc

IDXX:NSQ

IDEXX Laboratories Inc

Actions
Health CareMedical Equipment and Services
  • Price (USD)511.30
  • Today's Change-0.97 / -0.19%
  • Shares traded360.50k
  • 1 Year change+13.55%
  • Beta1.3258
Data delayed at least 15 minutes, as of Sep 18 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year IDEXX Laboratories Inc grew revenues 8.72% from 3.37bn to 3.66bn while net income improved 24.44% from 679.09m to 845.04m.
Gross margin60.41%
Net profit margin22.34%
Operating margin28.62%
Return on assets26.91%
Return on equity63.25%
Return on investment39.47%
More ▼

Cash flow in USDView more

In 2023, IDEXX Laboratories Inc increased its cash reserves by 303.33%, or 341.39m. The company earned 906.51m from its operations for a Cash Flow Margin of 24.76%. In addition the company used 125.25m on investing activities and also paid 442.00m in financing cash flows.
Cash flow per share11.53
Price/Cash flow per share43.63
Book value per share19.16
Tangible book value per share12.87
More ▼

Balance sheet in USDView more

IDEXX Laboratories Inc has a Debt to Total Capital ratio of 37.42%, a lower figure than the previous year's 63.71%.
Current ratio1.37
Quick ratio1.03
Total debt/total equity0.5979
Total debt/total capital0.3742
More ▼

Growth rates in USD

Year on year, growth in earnings per share excluding extraordinary items increased 25.36%. Additionally, five year annualized earnings per share growth is in-line with the industry average relative to its peers.
EPS growth(5 years)18.62
EPS (TTM) vs
TTM 1 year ago		7.03
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.